📄 genetic and genomic medicine

Sickle Cell Disease Demographics and Clinical Epidemiology in Gambian Urban and Rural Cohorts Retrospective Analysis

This retrospective analysis of 840 Gambian SCD patients reveals low rates of acute crises and chronic complications despite the absence of hydroxyurea, while confirming that penicillin prophylaxis significantly reduces infection and crisis rates and folic acid supplementation is associated with higher hemoglobin levels.

Original authors: Dibbasey, M., Esoh, K., Susso, B., Forrest, K., Sonko, B., Makalo, L., Oriero, E., Cheng, N. I., Amenga-Etego, L., Cerami, C., Amambua-Ngwa, A.

Published 2026-07-07

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Dibbasey, M., Esoh, K., Susso, B., Forrest, K., Sonko, B., Makalo, L., Oriero, E., Cheng, N. I., Amenga-Etego, L., Cerami, C., Amambua-Ngwa, A.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The Big Picture: A Tale of Two Villages

Imagine two towns in The Gambia: Keneba, a quiet rural village surrounded by fields, and Fajara, a bustling city neighborhood. In both towns, there are people living with Sickle Cell Disease (SCD). Think of SCD like a car with a faulty engine that occasionally sputters and stalls (causing pain and illness).

The researchers acted like detectives, looking back through the "maintenance logs" (medical records) of 840 patients in these two towns. Their goal was to see how often these cars sputtered, what caused the breakdowns, and whether the mechanics (doctors) had the right tools to fix them.

The Surprise: A Quiet Ride Without the "Super-Tool"

Usually, in wealthy countries, doctors have a "super-tool" called Hydroxyurea that acts like a high-performance fuel additive, smoothing out the engine so it rarely breaks down.

The Big Discovery: The researchers found that nobody in these Gambian towns was using this super-tool. Despite this, the patients were doing surprisingly well.

The Result: Most patients (over 99%) had very few breakdowns. In fact, 67% of the rural patients and 92% of the city patients had no recorded long-term damage to their bodies.
The Analogy: It's like driving a car with a known engine flaw for years without the premium fuel additive, yet the car is still running smoothly and hasn't crashed. This suggests that the "engine" in these specific Gambian patients might be naturally more resilient, or that other simple factors are keeping them safe.

The Real Heroes: Simple, Low-Cost Fixes

Even without the "super-tool," the patients were using two simple, everyday "maintenance kits" that made a huge difference:

Folic Acid (The Nutrient Booster):
- What it did: The more often patients took folic acid (a simple vitamin), the stronger their "fuel tank" (hemoglobin levels) remained.
- The Analogy: Think of folic acid as regular oil changes. It didn't fix the engine flaw, but it kept the engine lubricated and running efficiently.
Penicillin (The Bodyguard):
- What it did: Patients who took penicillin (an antibiotic) to prevent infections had fewer "stalls" (sickle cell crises) and fewer infections.
- The Analogy: Imagine a bodyguard standing at the car door. When the bodyguard (penicillin) was present, the car was less likely to get attacked by "bad guys" (bacteria), which often trigger the engine to sputter. The study found that by stopping the infections, the penicillin indirectly stopped the painful crises.

What Didn't Matter (The Red Herrings)

The researchers looked for clues about what made the cars break down more often. They checked:

Age: Did older cars break down more? No.
Gender: Did the car's color (male/female) matter? No.
Season: Did the rainy season cause more breakdowns? Not significantly.
Diagnosis Time: Did finding out about the engine flaw early help? Not in a way that changed the breakdown rate in this specific study.

The Twist: The only thing that seemed to change the frequency of breakdowns was distance. In the rural town, people who lived farther away from the clinic actually had fewer recorded crises. The researchers suspect this might be because if you live far away, you might not come to the clinic for every small "sputter," so it doesn't get written down in the logbook.

The Missing Pieces

The study also highlighted two major gaps:

Late Diagnosis: Many patients weren't diagnosed until they were already older (often after age 5). It's like waiting until the car is already smoking to realize the engine is faulty. The study suggests that checking every baby at birth (Newborn Screening) would be a game-changer.
No "Super-Tool" Records: There was absolutely no record of anyone using Hydroxyurea. While the patients are doing okay with simple vitamins and antibiotics, the study notes that adding the "super-tool" could likely make the ride even smoother.

The Bottom Line

This study is a story of resilience. It shows that in The Gambia, people with Sickle Cell Disease are living with fewer severe complications than expected, even without the most advanced modern medication. It proves that simple, consistent care—like taking vitamins and using antibiotics to prevent infection—acts as a powerful shield. However, to make the ride even safer, the study suggests we need to catch the "engine flaw" earlier in life and, if possible, introduce the advanced "fuel additive" (Hydroxyurea) to the mix.

Technical Summary: Sickle Cell Disease Demographics and Clinical Epidemiology in Gambian Urban and Rural Cohorts

Problem Statement
Sickle Cell Disease (SCD) is a prevalent monogenic disorder, with approximately 75% of global cases occurring in sub-Saharan Africa. Despite this burden, empirical data regarding the natural history, clinical burden, and non-genetic modifiers of SCD in the region remain scarce. In low- and middle-income countries (LMICs) like The Gambia, challenges such as delayed diagnosis, limited access to specialist care, and the absence of disease-modifying therapies like hydroxyurea contribute to high morbidity and premature mortality. While prior studies in The Gambia have focused on specific age groups (e.g., children aged 5–15) or specific complications (e.g., invasive bacterial infections), there is a lack of comprehensive epidemiological characterization across all age groups. This study addresses the gap in understanding the real-world clinical landscape of SCD in The Gambia, specifically examining demographic characteristics, complication burdens, and the impact of non-genetic factors and routine supportive care in the absence of hydroxyurea.

Methodology
The study employed a retrospective cohort design analyzing 8,402 medical records from 840 confirmed HbSS genotype patients registered at two distinct sites: the MRCG Keneba clinic (rural setting, $N=148$ ) and the MRCG Fajara clinic (urban setting, $N=692$ ). Data were extracted from the Keneba Electronic Medical Record System (KEMReS, active since 2009) and the Fajara Clinic Electronic Medical Record System (EMRS, active since 2016).

Data Processing: Records were filtered to include only patients with confirmed HbSS genotypes, verified via alkaline-based hemoglobin electrophoresis. Patients with HbSC or other genotypes were excluded.
Variables: The analysis covered demographic data (age, gender, ethnicity, age at diagnosis), clinical events (SCD crises, infections, hospitalizations, transfusions), chronic complications (stroke, leg ulcers, organ damage), and laboratory indices (hemoglobin, white cell count, liver/kidney function).
Statistical Analysis: Descriptive statistics summarized demographics and complication frequencies. Clinical outcomes were standardized per patient-year. To assess associations between non-genetic correlates (age, seasonality, geography) and clinical events, negative binomial regression models were employed to handle overdispersion and zero-inflation in count data. Linear models were used to assess the association between folic acid prescriptions and hemoglobin levels. Propensity score matching was utilized to evaluate the effect of penicillin exposure on clinical outcomes.

Key Results

Demographics: The study population exhibited a wide age spectrum (0–80 years), with a notable proportion of long-term survivors (patients >30 years). The median age at diagnosis was delayed (9.8 years in Keneba, 7.0 years in Fajara), with most diagnoses occurring after age 5.
Disease Severity and Complications: The study observed a predominantly mild clinical phenotype.
- Acute Events: Rates of SCD crises and infections were low in both cohorts (Keneba: 0.57 crises/patient-year; Fajara: 0.63 crises/patient-year). Over 99% of patients experienced ≤3 SCD crises per patient-year.
- Chronic Complications: A significant majority of patients had no documented chronic complications (67.6% in Keneba; 92.9% in Fajara).
- Mortality: Seven deaths were recorded in the rural cohort (attributed to malnutrition, stroke, leg ulcers, and severe anemia); no mortality was reported in the urban cohort records.
Treatment and Supportive Care: There was no documented evidence of hydroxyurea use in either cohort during the study period. However, supportive care was widely utilized:
- Folic Acid: Increased frequency of folic acid prescriptions was significantly associated with higher hemoglobin levels ( $\beta_{Fajara}=1.31, P=0.005$ ; $\beta_{Keneba}=1.20, P<0.001$ ).
- Penicillin Prophylaxis: Penicillin use was associated with reduced rates of infection (IRR: 0.85 in Fajara; 0.93 in Keneba) and, through propensity score analysis, a reduced rate of SCD crises (IRR: 0.67, $P<0.001$ ).
Non-Genetic Correlates:
- Age at diagnosis, gender, and seasonality were not significantly associated with SCD crisis rates or other clinical outcomes in the multivariate models.
- In the rural cohort, greater distance from the clinic was inversely associated with SCD crisis rates, while non-residents of the local region had higher clinic visit rates.
- In the urban cohort, older age was associated with fewer crises and transfusion rates.

Significance and Claims
The authors claim this study provides one of the first large-scale analyses of SCD clinical data in The Gambia, offering critical insights into the disease's natural history in a resource-limited setting without hydroxyurea therapy. The study highlights that despite the absence of disease-modifying therapies, the Gambian SCD population exhibits a milder clinical phenotype with low rates of acute events and chronic complications compared to other African cohorts (e.g., Cameroon).

The findings underscore the efficacy of simple, low-cost supportive interventions. The observed association between penicillin prophylaxis and reduced infection/crisis rates, and between folic acid and improved hemoglobin levels, reinforces the importance of these basic measures in improving outcomes. The study concludes that the delayed diagnosis observed in the cohorts likely limits the potential for early intervention and suggests that implementing universal newborn screening programs is imperative for The Gambia. Furthermore, the data establishes a baseline for future research into genetic modifiers (such as HbF levels and haplotypes) that may contribute to the observed mild phenotypes and supports the need for expanded access to hydroxyurea to further reduce the disease burden.